Brief Article
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 14, 2014; 20(10): 2688-2694
Published online Mar 14, 2014. doi: 10.3748/wjg.v20.i10.2688
Figure 1
Figure 1 DNA sequences of CD14-260C/T and CD14-651C/T polymorphisms. A: CD14-260C/T polymorphism; B: CD14-651C/T polymorphism.
Figure 2
Figure 2 Effect of CD14-260C/T polymorphism and lipopolysaccharide treatment on CD14 expression. Luciferase reporter vectors carrying the CD14-260C/T polymorphism and renilla luciferase reporter vector pRL-TK were co-transfected into gastric cancer MGC-803 cells and treated with 1 μg/mL of LPS. Later, cells were lysed and assayed for luciferase activity. Data are normalized to the mean ± SE value of Firefly/Renilla. bP < 0.01 vs control cells without LPS; dP < 0.01 vs p260C-transfected cells without LPS treatment; fP < 0.01 vs control cells with LPS treatment; hP < 0.01 vs p260C-transfected cells with LPS treatment. LPS: Lipopolysaccharide.